Rotavirus disease burden, Nicaragua 2001-2005: defining the potential impact of a rotavirus vaccination program
- PMID: 20022778
- DOI: 10.1016/j.ijid.2009.08.014
Rotavirus disease burden, Nicaragua 2001-2005: defining the potential impact of a rotavirus vaccination program
Abstract
Background: In October 2006, a rotavirus vaccine was introduced in Nicaragua for routine immunization of all children. We document the baseline diarrheal disease burden in Nicaragua prior to the vaccine program to facilitate future studies to measure vaccine impact.
Methods: We analyzed national data for 2001-2005 on total acute gastroenteritis healthcare visits, hospitalizations, and mortality in Nicaraguan children aged <5 years.
Results: Prior to vaccine introduction, by age 5 years, one in four Nicaraguan children required an outpatient consultation, one in 34 were hospitalized, and one in 2487 died from rotavirus-associated diarrhea, representing approximately 41,122 outpatient visits, 4460 hospitalizations, and 60 deaths per year that are preventable through vaccination. Almost half of the total acute gastroenteritis burden was in children <1 year of age. Two distinct seasonal peaks were noted in acute gastroenteritis hospitalizations and deaths.
Conclusions: Existing data sources on all-cause acute gastroenteritis could be useful for establishing diarrhea disease burden and monitoring trends after vaccine introduction. Blunting of winter season peaks in rates of diarrhea, particularly among children aged <1-2 years, would be a useful indicator of impact from rotavirus vaccination.
Published by Elsevier Ltd.
Similar articles
-
Uptake of rotavirus vaccine and national trends of acute gastroenteritis among children in Nicaragua.J Infect Dis. 2009 Nov 1;200 Suppl 1:S125-30. doi: 10.1086/605053. J Infect Dis. 2009. PMID: 19821709
-
Active, population-based surveillance for severe rotavirus gastroenteritis in children in the United States.Pediatrics. 2008 Dec;122(6):1235-43. doi: 10.1542/peds.2007-3378. Pediatrics. 2008. PMID: 19047240
-
Projected Impact of the new rotavirus vaccination program on hospitalizations for gastroenteritis and rotavirus disease among US children <5 years of age during 2006-2015.J Infect Dis. 2009 Nov 1;200 Suppl 1:S49-56. doi: 10.1086/605036. J Infect Dis. 2009. PMID: 19817614
-
Update on Rotarix: an oral human rotavirus vaccine.Expert Rev Vaccines. 2009 Dec;8(12):1627-41. doi: 10.1586/erv.09.136. Expert Rev Vaccines. 2009. PMID: 19943758 Review.
-
Rotavirus vaccination within the South African Expanded Programme on Immunisation.Vaccine. 2012 Sep 7;30 Suppl 3:C14-20. doi: 10.1016/j.vaccine.2012.04.018. Vaccine. 2012. PMID: 22939015 Review.
Cited by
-
Prevention of rotavirus infections in vitro with aqueous extracts of Quillaja Saponaria Molina.Future Med Chem. 2010 Jul;2(7):1083-97. doi: 10.4155/fmc.10.206. Future Med Chem. 2010. PMID: 20725585 Free PMC article.
-
Risk Factors for Norovirus Gastroenteritis among Nicaraguan Children.Am J Trop Med Hyg. 2017 Sep;97(3):937-943. doi: 10.4269/ajtmh.16-0799. Epub 2017 Jul 19. Am J Trop Med Hyg. 2017. PMID: 28722577 Free PMC article.
-
Rotavirus vaccine RIX4414 (Rotarix™): a pharmacoeconomic review of its use in the prevention of rotavirus gastroenteritis in developing countries.Pharmacoeconomics. 2011 Nov;29(11):989-1009. doi: 10.2165/11207210-000000000-00000. Pharmacoeconomics. 2011. PMID: 21988293 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical